First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
The bull case is simple: analysts see revenue climbing from $64M to $120M as recent data from phase 2 trials shows a 75% efficacy rate in dmd patients, significantly higher than industry standards.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.